Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 17/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183719 | 0.78 | CYP2E1 (0.51) | CYP2C9CYP1A2CYP19A1 | |
| SCHEMBL19397285 | 0.75 | NOTUM (0.47) | — | |
| SCHEMBL21849215 | 0.74 | NOTUM (0.37) | CYP2C9CYP1A2AMY1APKMGABRA1 | |
| SCHEMBL21863404 | 0.74 | CHRNB2 (0.40) | CYP11B2CYP11B1CYP2C9CYP1A2 | |
| SCHEMBL823824 | 0.73 | GABRA1 (0.46) | PKMCYP19A1GABRA1GABRB2 | |
| SCHEMBL24656661 | 0.73 | NR2E1 (0.44) | CYP2C9CYP1A2AMY1APKMGABRA1 | |
| SCHEMBL21849238 | 0.73 | CYP1A2 (0.33) | CYP11B2CYP11B1CYP2C9CYP1A2AMY1A | |
| SCHEMBL21849237 | 0.73 | OPRD1 (0.44) | CYP2C9CYP1A2AMY1APKM | |
| SCHEMBL21848986 | 0.73 | CYP11B2 (0.38) | CYP11B2CYP11B1CYP2C9CYP19A1 | |
| SCHEMBL19728977 | 0.73 | CYP2A6 (0.46) | CYP11B2CYP11B1CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP11B2 1907/4885CYP11B1 1560/4885CYP2C9 773/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP11B2 1907/4885CYP11B1 1560/4885CYP2C9 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.